Resultados de la búsqueda 241-250 of 768 for visual+hallucinations

1. Cirugía - Ensayos clínicos - Mayo Clinic

   Rochester, Minn. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or ...

2. Epilepsia - Síntomas y causas - Mayo Clinic

   La epilepsia, también conocida como trastorno convulsivo, es una afección cerebral que causa convulsiones recurrentes. Hay muchos tipos de epilepsia.

3. Neurología - Ensayos clínicos - Mayo Clinic

   ... vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor ...

4. Neurología - Ensayos clínicos - Mayo Clinic

   ... vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor ...

5. Neurología - Ensayos clínicos - Mayo Clinic

   ... vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor ...

6. Neurología - Ensayos clínicos - Mayo Clinic

   ... vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor ...

7. Neurología - Ensayos clínicos

   ... vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor ...

8. Neurología - Ensayos clínicos - Mayo Clinic

   Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and ...

9. Ensayos clínicos - Neurología

   To describe the clinical features along with treatment outcomes of a cohort of patients with a diagnosis of NMOSD after the latest revised criteria in 2015 by ...

10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...